Laryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation
|
|
- Irene Roberts
- 5 years ago
- Views:
Transcription
1 1
2 Laryngeal Preservation Using Radiation Therapy 1903: Schepegrell was the first to perform radiation therapy for the treatment of laryngeal cancer Conventional external beam radiation produced disappointing results for advanced stage cancers (Local control: 65% for T3 glottic, 60% for T4 glottic and 50% for T4 supraglottic) Hyperfractionated regimen (bid XRT): improved local control by approximately 20% Accelerated dose regimen or accelerated regimen with concomitant boost All regimen resulted in improved local control but no survival benefit and increased toxicity Chemotherapy and Organ Preservation 1982: At ASCO, WSU present the first report of induction chemotherapy in 34 patients Chemosensitive tumors were also radiosensitive This led to the hypothesis that chemotherapy could be used to select tumors for effective treatment without laryngectomy This small pilot study led to the design of the VA Laryngeal Cooperative Study #268 2
3 3
4 Larynx Preservation Larynx Preservation Long Term Quality of Life RANDOMIZED PATIENTS Larynx preserved Laryngectomy PATIENTS ALIVE With larynx Without larynx (62%) (66%) 27 Measure SF-36* Mental health HNQOL* Pain Speech Mod./severe depression Pre-treatment Post-treatment Surg + XRT (n=25) Chemo + XRT (n=21) % 11% 28% 15% * All domains better for chemo + XRT, except speech P value <.05 <.05 N.S. Key Findings Important in Design of Future Studies Surgery is important component, salvage is challenging Neck management may differ from primary, (persistent occult disease 30-40% of N2,3) Systemic treatment of micrometastases must be considered No improvement in survival compared to surgery 4
5 EORTC Trial Stage II-IV cancers of the pyriform sinus or aryepiglottic fold induction chemo plus definitive radiation therapy in CRs vs. conventional treatment Results in 194 patients with 51 months median follow-up: equivalent survival EORTC Trial fewer failures at distant sites in the induction chemotherapy arm than in the immediate surgery arm (25% versus 36% respectively, p = 0.041). 5
6 R91-11 Phase III Trial to Preserve the Larynx Arm 1: Cisplatin/5-FU x 2 NR CR, PR cisplatin/5-fu x 1 surgery RT RT Arm 2: Radiation therapy with cisplatin Arm 3: Radiation therapy Patients entered Ineligible Eligibility pending Data pending Patient Enrollment Arm 1 Arm 2 Arm 3 Total Analyzable Median follow-up of surviving patients: 36 months Surgical Management Patients presenting with N2 or N3 neck disease (single node > 3 cm or multiple nodes) had a planned neck dissection 8 weeks after completing treatment Laryngectomy and neck dissection were performed for progression (induction arm) or persistent or recurrent local/regional disease (CT/XRT, RT arms). 6
7 Intergroup Trial R Overall Survival 76.5% Adequate patient numbers Homogeneous population Important Question: What is the real benefit of adding chemotherapy to radiation with respect to survival, larynx preservation and morbidity? % A L I V E % 75.7% 59.9% Induction CT Concurrent CT (p=0.70 vs. Induction) RT alone (p=0.59 vs. Induction) YEARS FROM RANDOMIZATION 54.0% 53.4% % P R E S E R V E D Larynx Preservation Induction 88.0% 73.6% 59.3% Concurrent (p= vs. Induction) RT alone (p=0.22 vs. Induction) YEARS FROM RANDOMIZATION 84.5% 70.8% 63.5% % A L I V E (N E D) Disease-Free Survival % 54.5% 42.9% Induction CT Concurrent CT (p=0.56 vs. Induction) RT alone (p= vs. Induction) YEARS FROM RANDOMIZATION 44.2% 42.3% 30.4% 7
8 Distant Metastases 93.1% 91.8% 84.6% 86.6% 85.9% 75.8% Important Points in Interpreting These Data % F A I L E D Induction CT Concurrent CT (p=0.97 vs. Induction) Timing of salvage laryngectomy is potentially confusing endpoint (early salvage may be better) The success of salvage surgery must be known RT alone (p=0.044 vs. Induction) YEARS FROM RANDOMIZATION RT Survival by Salvage Laryngectomy VA CSP268 Survival by Salvage Laryngectomy Weber, et al, Arch Oto-HNS,
9 COMPLICATIONS ASSOC. WITH CONCURRENT CHEMO/XRT Stricture Radiation necrosis Chronic laryngeal edema Trach dependence Swallowing disorders Michigan Chemoselection Approach Search for tumor characteristics, clinical and biologic, that predict success VA laryngeal study taught us that patients who had a CR after single dose were the most successful 9
10 Organ Preservation by Cycle of Chemotherapy CR BY CYCLE (N) % CR ORGAN PRES. 2 cycles (49) 30% 86% 3 cycles (20) 12% 70% Patient Population Patient Population Stage III 46 (47%) T 2 = 9 N 0 = 53 (55%) Stage IV 51 (53%) T 3 = 56 N 1 = 17 TOTAL 97 T 4 = 32 N 2 = 24 N 3 = 3 10
11 Patient Population Primary Tumor Response After One Cycle CR = 15 (16%) Supraglottic Glottic (77%) (23%) PR = 58 (61%) NR = 22 (23%) *2 patients were N/E, response did not differ by T class, Stage or site Overall Survival Fig 1. Overall survival 25 deaths: 13 HNSCC, 12 Other Cause of HNSCC Deaths: Local/regional 4 Distant Metastases 9 Median Follow up=41.9 months Urba, S. et al. J Clin Oncol; 24:
12 UMCC 9520 Overall Survival by T Class Fig 2. Disease-free survival 1.00 % Overall Survival T2+T3 (n=65) Urba, S. et al. J Clin Oncol; 24: Laryngeal Preservation Rate = 71% Fig 3. Survival of patients with larynx and free of disease Laryngectomy = 28/97 (29%) Timing of laryngectomy Planned after NR = 22* Late salvage = 6 (13-36 months) *3 non-responders did not undergo laryngectomy because of myocardial infarct, metastatic or unresectable disease. Urba, S. et al. J Clin Oncol; 24:
13 Survival 3 Year COMPARISON OF PATIENT POPULATIONS UMCC 9520 VA-CSP 268 Overall Survival = 85% (95% CI= 71-91%) Disease Free Survival = 78% (69-89%) Laryngectomy-free Survival = 61% (48-70%) Larynx preservation rate = 71% Median f/u = 29 months N Glottis Supraglottis T 2 T 3 T 4 N 0,1 N 2, % 77% 9% 56% 33% 72% 28% % 63% 9% 65% 26% 72% 28% Comparison of Survival:VA Larynx Trial vs UMCC9520 COMPARISON OF PATIENT POPULATIONS Intergroup R91-11 UMCC 9520 N Glottis Supraglottis T 2 T 3 T 4 N 0,1 N 2, 3 Male Female % 68% 9% 81% 10% 69% 31% 77% 23% 97 23% 77% 9% 58% 32% 72% 29% 79% 21% 13
14 Survival Comparisons Three Trials 3 YEAR SURVIVAL UMCC-9520 CT/XRT RT VA-CSP 268 Overall 80% 70% 53% Comparison with Historic Controls U of M V.A. Int 9111* 5-Year Survival Overall 71% 43% 55% Disease-Free 78% 55% - Laryngectomy- Free 61% 58% 34% *ctx/xrt arm Fig 4. Survival of patients with organ preservation versus laryngectomy Take Home Points A single cycle of induction chemotherapy was highly successful in selecting patients for organ preservation with chemo/radiation. Urba, S. et al. J Clin Oncol; 24:
15 Take Home Points Take Home Points Overall 3-year survival rates appear improved with this approach to larynx preservation compared to historical controls. Surgery remains a critical component of treatment and early salvage appears to be more effective than late salvage Randomized comparison to standard treatment regimens is necessary to confirm the survival advantage of this approach French HN Onc Trial TPF vs PF Calais, 2008 Calais,
16 Calais, 2008 Calais, 2008 R A N D O M I Z E Sequential Combined Modality Therapy A Phase III Study: TAX 324 TPF vs PF Followed by Chemoradiotherapy T P F P F cbdca auc 1.5 Weekly EUA Daily Radiotherapy Surgery TPF: Docetaxel 75 D1 + Cisplatin 100 D1 + 5-FU 1000 CI- D1-4 Q 3 weeks x3 PF: Cisplatin 100 D1 + 5-FU 1000 CI-D1-5 Q 3 weeks x 3 Posner NEJM, 2007 Characteristics of Hypopharynx and Larynx Cases Treated On TAX 324 TPF PF P Number Hypopharynx 43 (48%) 34 (45%) Larynx 47 (52%) 42 (55%) Median Age (Range) 56 (39-82) 59 (37-80) P=.21 T Stage T1/2 T3 T4 Nodal Stage N0/1 N2 N3 Clinical Stage III IV Posner, Ann Oncol (17%) 35 (39%) 40 (44%) 43 (47%) 35 (39%) 12 (13%) 22 (24%) 68 (76%) 17 (22%) 33 (43%) 26 (34%) 33 (46%) 31 (40%) 12 (15%) 22 (29%) 54 (71%) P=.37 P=.81 P=.60 16
17 Larynx and Hypopharynx Survival and Progression Free Survival Laryngeal Cancer in the United States: Changes in Demographics, Patterns of Care, and Survival TPF PF P Number Overall Survival Median, mo (range) 2 Year 3 Year Hazard ratio PFS ( Equivalent to LFS) Median, mo (range) 2 Year 3 Year Hazard ratio 59 (31-NR) 24 (13-42) 64% (54-74%) 50% (38-61%) 57% (46-68%) 40% (29-52%) 0.62 ( ) (12-59) 48% (37-58%) 43% (32-54%) 11 (8-14) 33% (22-43%) 29% (19-40%) 0.66 ( ).032 Posner, Ann Oncol 2009 The Laryngoscope Volume 116, Issue S111, pages 1-13, 2 JAN 2009 DOI: /01.mlg Laryngeal Cancer in the United States: Changes in Demographics, Patterns of Care, and Survival Case 67 year old man Mild stridor Hoarse for 8 months Cord immobile Imaging The Laryngoscope Volume 116, Issue S111, pages 1-13, 2 JAN 2009 DOI: /01.mlg
18 Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion The Laryngoscope Volume 119, Issue 8, pages , 5 JUN 2009 DOI: /lary Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion Univ of Chicago T4 Study Similar survival to RTOG % persistent tracheostomy 15% permanent G tube 30% normal, 60% hoarseness and 10% aphonic The Laryngoscope Volume 119, Issue 8, pages , 5 JUN 2009 DOI: /lary
19 Summary of Treatment Approaches Consider surgery for small T stage, advance neck stage Organ preservation strategies are ideal for T3 Surgery is the treatment of choice for T4 cancers 19
20 Looking to the Future Organ Preservation Exciting time for new paradigms Potent chemo - high CR rates Beginning to understand the biology Tailored Treatment Matrix Factors Surgery Radiation Chemo Biologics Proliferation Low High Nl to low + Questions? Immunogenic High CD8? High CD4? Tumor Volume High Low Vascular Low Host Immune Intact Poor Partial? p53 Express. p53- p53- p53+ + p53 Mutation wtp53 wtp53 mutp53 + Apoptosis Inc Bclx Low Bclx Low Bclx + EGFR Inc EGFR Low EGFR +/- + Growth Pattern Low High High? VEGF Low High High + HPV + +/- -? p53 Ab + - -? 20
The International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
More informationLaryngeal Conservation
Laryngeal Conservation Sarah Rodriguez, MD Faculty Advisor: Shawn Newlands, MD, PhD The University of Texas Medical Branch Department of Otolaryngolgy Grand Rounds Presentation February 2005 Introduction
More informationOrgan-Preservation Strategies in head and neck cancer. Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari
Organ-Preservation Strategies in head and neck cancer Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari Larynx Hypopharynx The goal of treatment is to achieve larynx preservation
More informationThe PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
More informationLarynx Hypopharynx. Therapy algorithms. Why larynx preservation at all? State of the art Jean Louis Lefebvre,Lille Jan Klozar,Prague
Larynx Hypopharynx Moderation Rainald Knecht,Hamburg State of the art Jean Louis Lefebvre,Lille Debate pro CRT Jan Klozar,Prague contra CRT Marshall Posner,Boston Clinical cases all Therapy algorithms
More informationSequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer. Dr P Vijay Anand Reddy Director Apollo Cancer Hospital
Sequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer Dr P Vijay Anand Reddy Director Apollo Cancer Hospital H&N Ca - Disease Burden 15-20% of all cancers in India, 8% worldwide
More informationMANAGEMENT OF CA HYPOPHARYNX
MANAGEMENT OF CA HYPOPHARYNX GENERAL TREATMENT RECOMMENDATIONS BASED ON HYPOPHARYNX TUMOR STAGE For patients presenting with early-stage definitive radiotherapy alone or voice-preserving surgery are viable
More informationORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER
ORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER Vasu Divi, MD, 1 * Francis P. Worden, MD, 1,2 * Mark E. Prince, MD, 1 Avraham Eisbruch, MD, 3 Julia S. Lee, MD, 4
More informationEmerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
More informationNeoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck. Mei Tang, MD
Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD Head and Neck Cancer Worldwide New cases : 644,000 Cancer deaths: 350,000 About 5% of all cancers Local Recurrence:
More informationHead and NeckCancer: multi-modal therapeuticintegration
Head and NeckCancer: multi-modal therapeuticintegration P. Ponticelli, L. Lastrucci, R. De Majo, A. Rampini U.O.C. Radioterapia Ospedale S. Donato ASL 8 -AREZZO Summary Biological considerations Clinical
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationSelf-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
More informationHead and Neck cancer
Head and Neck cancer Medical Oncologist s Role in Multidisciplinary Teams - Focus on Adjuvant & Neo-adjuvant Therapy - Hye Ryun Kim, M.D. Yonsei Cancer Center, Medical Oncology Contents I. Introduction
More informationLaryngeal and hypopharyngeal cancers
Laryngeal and hypopharyngeal cancers Induction Chemotherapy in combined modality approaches Atenas 16.09.2017 Ana Ferreira Castro, MD Medical Oncology Centro Hospitalar do Porto Instituto de Ciências Biomédicas
More informationSome Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer
Bladder Cancer Role of Radiation in Bladder Sparing David C. Beyer M.D., FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Primary Radiation for Bladder Cancer No modern surgery / XRT randomized
More informationSanguineti s (2)Comment: When it was initially published in 2003 with a median follow-up of 3.8 years (4), the RTOG study led to a change in
Commento di due Soci AIRO pubblicati su due prestigiose riviste internazionali al Trial della forastiere et al. Long term results of RTOG:91-11 (a cura di Dr. Russi e Dr. Testolin )! Forastiere)et)al.)Long/Term)Results)of)RTOG)91/11:)A)Comparison)of)
More informationClinical Discussion. Dr Pankaj Chaturvedi. Professor and Surgeon Tata Memorial Hospital
Clinical Discussion Dr Pankaj Chaturvedi Professor and Surgeon Tata Memorial Hospital chaturvedi.pankaj@gmail.com 47/M/smoker Hopkins : Transglottic lesion No cartilage infiltration but sclerosis Left
More informationThe management of advanced supraglottic and
ORIGINAL ARTICLE ORGAN PRESERVATION FOR ADVANCED LARYNGEAL CARCINOMA Robert L. Foote, MD, 1 R. Tyler Foote, 1 Paul D. Brown, MD, 1 Yolanda I. Garces, MD, 1 Scott H. Okuno, MD, 2 Scott E. Strome, MD 3 1
More informationHead and Neck Cancer:
Head and Neck Cancer: Robert Haddad M.D. Clinical Director Head and Neck Oncology Program Dana Farber Cancer Institute Boston, MA Predictive Biomarkers: HPV Abstract 6003: Survival Outcomes By HPV Status
More informationNew Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
More informationUse of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer. American Society of Clinical Oncology Clinical Practice Guideline
Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer American Society of Clinical Oncology Clinical Practice Guideline Introduction ASCO convened an Expert Panel to develop recommendations
More informationThe International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology 2018 www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
More informationHead and Neck Reirradiation: Perils and Practice
Head and Neck Reirradiation: Perils and Practice David J. Sher, MD, MPH Department of Radiation Oncology Dana-Farber Cancer Institute/ Brigham and Women s Hospital Conflicts of Interest No conflicts of
More informationNeoplasie del laringe Diagnosi e trattamento
Neoplasie del laringe Diagnosi e trattamento Venerdì 22 maggio 2015 Alessandria Trattamenti non chirurgici: Preservazione d organo, malattia localmente avanzata Marco C Merlano A.O. S.Croce e Carle, Ospedale
More informationHead & Neck Cancer: When to Irradiate
Head & Neck Cancer: When to Irradiate ESO-ESMO Latin-America 2018 Talented students colleagues 1 > 15 different diseases for RT strategies NC NP OC OP H L 2 HPV Prognostic Marker >2010 Trial Cases Marker
More informationWojciech K. Mydlarz, M.D. Pharyngocutaneous Fistulas after Salvage Laryngectomy: Need for Vascularized Tissue
Wojciech K. Mydlarz, M.D. Pharyngocutaneous Fistulas after Salvage Laryngectomy: Need for Vascularized Tissue Disclosures No Relevant Financial Relationships or Commercial Interests Educational Objectives
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationSurvey of Laryngeal Cancer at SBUH comparing 108 cases seen here from to the NCDB of 9,256 cases diagnosed nationwide in 2000
Survey of Laryngeal Cancer at comparing 108 cases seen here from 1998 2002 to the of 9,256 cases diagnosed nationwide in 2000 Stony Brook University Hospital Cancer Program Annual Report 2002-2003 Gender
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationThomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX
Thomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX Disclosures I have nothing to disclose. 3 Changing Role of Surgery N=42,688 Chen Ay et al. Larygoscope. 2007; 117:16-21
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Prague July 2016 State of the art: Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre Aim to discuss Background The trials
More informationChemoselection as a Strategy for Organ Preservation in Patients with T4 Laryngeal Squamous Cell Carcinoma with Cartilage Invasion
The Laryngoscope VC 2009 The American Laryngological, Rhinological and Otological Society, Inc. Chemoselection as a Strategy for Organ Preservation in Patients with T4 Laryngeal Squamous Cell Carcinoma
More informationPre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
More informationThe Role of Docetaxel in the Treatment of Head and Neck Cancer
GBMC Head and Neck Conference The Role of Docetaxel in the Treatment of Head and Neck Cancer Simon Best December 7, 2007 Needs assessment: Providers who participate in the care of head and neck cancer
More informationRT +/- Surgery. Concurrent ChemoRT +/- Surgery
Molecular targeted approaches to head and neck cancer Lillian L. Siu Department of Medical Oncology & Hematology Princess Margaret Hospital, University of Toronto Locally Advanced HNSCC Locally Advanced
More informationSAMO MASTERCLASS HEAD & NECK CANCER. Nicolas Mach, PD Geneva University Hospital
SAMO MASTERCLASS HEAD & NECK CANCER Nicolas Mach, PD Geneva University Hospital Epidemiology Prevention Best treatment for localized disease Best treatment for relapsed or metastatic disease Introduction
More informationCase Scenario 1. Pathology: Specimen type: Incisional biopsy of the glottis Histology: Moderately differentiated squamous cell carcinoma
Case Scenario 1 History A 52 year old male with a 20 pack year smoking history presented with about a 6 month history of persistent hoarseness. The patient had a squamous cell carcinoma of the lip removed
More informationPost-Operative Concurrent Chemoradiation with Mitomycin-C for Advanced Head and Neck Cancer
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 2006 Post-Operative Concurrent Chemoradiation with Mitomycin-C for
More informationTitle. CitationInternational Journal of Clinical Oncology, 20(6): 1. Issue Date Doc URL. Rights. Type. File Information
Title Clinical outcomes of weekly cisplatin chemoradiother Sakashita, Tomohiro; Homma, Akihiro; Hatakeyama, Hir Author(s) Takatsugu; Iizuka, Satoshi; Onimaru, Rikiya; Tsuchiy CitationInternational Journal
More informationConcurrent Chemo- and Radiotherapy for Ororpharynx Cancer
Concurrent Chemo- and Radiotherapy for Ororpharynx Cancer Faye Johnson MD, PhD Associate Professor Thoracic/Head and Neck Medical Oncology August 2017 Objectives Review data that support concurrent chemo-
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationPersistent tracheostomy after primary chemoradiation for advanced laryngeal or hypopharyngeal cancer
ORIGINAL ARTICLE Persistent tracheostomy after primary chemoradiation for advanced laryngeal or hypopharyngeal cancer Paul A. Tennant, MD, * Elizabeth Cash, PhD, Jeffrey M. Bumpous, MD, Kevin L. Potts,
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationHPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationAccepted 20 April 2009 Published online 25 June 2009 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.21179
ORIGINAL ARTICLE DOCETAXEL, CISPLATIN, AND FLUOROURACIL INDUCTION CHEMOTHERAPY FOLLOWED BY ACCELERATED FRACTIONATION/CONCOMITANT BOOST RADIATION AND CONCURRENT CISPLATIN IN PATIENTS WITH ADVANCED SQUAMOUS
More informationORIGINAL ARTICLE. Salvage Surgery After Failure of Nonsurgical Therapy for Carcinoma of the Larynx and Hypopharynx
ORIGINAL ARTICLE Salvage Surgery After Failure of Nonsurgical Therapy for Carcinoma of the Larynx and Hypopharynx Sandro J. Stoeckli, MD; Andreas B. Pawlik, MD; Margareta Lipp, MD; Alexander Huber, MD;
More informationNEWER DRUGS IN HEAD AND NECK CANCER. Prof. Anup Majumdar. HOD, Radiotherapy, IPGMER Kolkata
NEWER DRUGS IN HEAD AND NECK CANCER Prof. Anup Majumdar HOD, Radiotherapy, IPGMER Kolkata 1 Included Oral cavity Nasal cavity Pharynx Larynx Lymph node in upper part of neck Excluded Brain Eye Cancer arising
More informationNasopharyngeal Cancer/Multimodality Treatment
Nasopharyngeal Cancer/Multimodality Treatment PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 22/10/2016 1 st Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More informationSimultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer
Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Dawn Gintz, CMD, RTT Dosimetry Coordinator of Research and
More informationT1/T2 LARYNX CANCER. Click to edit Master Presentation Date. Thomas J Gernon, MD Otolaryngology-Head and Neck Surgery
ADVANCES IN TREATMENT OF T1/T2 LARYNX CANCER Click to edit Master Presentation Date Thomas J Gernon, MD Otolaryngology-Head and Neck Surgery I have nothing to disclose CHANGING TRENDS IN HNSCC GLOTTIC
More informationGuillaume Janoray, Yoann Pointreau, Pascal Garaud, Sophie Chapet, Marc Alfonsi, Christian Sire, Eric Jadaud, Gilles Calais
JNCI J Natl Cancer Inst (016) 108(4): djv368 doi:10.1093/jnci/djv368 First published online December 16, 015 Article Long-Term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy
More informationState of the art for radiotherapy of SCCHN
State of the art for radiotherapy of SCCHN Less side effects Cured More organ & function preservation Head & neck cancer = 42 000 new cases / year in Europe Not cured Local failure Distant failure More
More informationA Prospective Phase II Trial of Deintensified Chemoradiation Therapy for Low Risk HPV Associated Oropharyngeal Squamous Cell Carcinoma
A Prospective Phase II Trial of Deintensified Chemoradiation Therapy for Low Risk HPV Associated Oropharyngeal Squamous Cell Carcinoma B. S. Chera 1, R. J. Amdur 2, J. E. Tepper 3, B. Qaqish 4, R. Green
More informationChemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
More informationjournal of medicine The new england Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer abstract
The new england journal of medicine established in 1812 november 27, 2003 vol. 349 no. 22 Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer Arlene A. Forastiere,
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationThe effect of induction chemotherapy followed by chemoradiotherapy in advanced head and neck cancer: a prospective study
International Journal of Research in Medical Sciences Nikam BM et al. Int J Res Med Sci. 2014 May;2(2):476-480 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: 10.5455/2320-6012.ijrms20140519
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationThe Role of Concurrent Chemo-radiotherapy in Patients with Head and Neck Cancers: A Review
The Role of Concurrent Chemo-radiotherapy in Patients with Head and Neck Cancers: A Review M.D. Al-Sarraf 1 1 Williams Beaumont Hospital, Royal Oak, Michigan, USA Introduction In the past, radiotherapy
More informationASCO Highlights Head and Neck Cancer
ASCO Highlights Head and Neck Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head &
More informationCURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,
More information5/20/ ) Haffty GB: Concurrent chemoradiation in the treatment of head and neck cancer. Hematol. Oncol. Clin: North Am.
Prague, 24-25 25 April 29 ALTERNATING CHEMORADIATION: FOR WHOM? M. Merlano MD Holy Cross Gen. Hospital Cuneo - Italy ALTERNATING CHEMORADIATION: FOR WHOM? Definition of alternating chemoradiation Targets
More informationProtocol of Radiotherapy for Head and Neck Cancer
106 年 12 月修訂 Protocol of Radiotherapy for Head and Neck Cancer Indication of radiotherapy Indication of definitive radiotherapy with or without chemotherapy (1) Resectable, but medically unfit, or high
More informationTreatment for Supraglottic Ca History: : Total Laryngectomy y was routine until early 50 s, when XRT was developed Ogura and Som developed the one-sta
Role of Laser Therapy in Laryngeal Cancer Khalid Hussain AL-Qahtani MD,MSc,FRCS(c) MSc Assistant Professor Consultant of Otolaryngology Advance Head & Neck Oncology, Thyroid & Parathyroid,Microvascular
More informationComparative study of Gemcitabine versus Cisplatin concurrent with radiotherapy for locally advanced head and neck cancer
Journal of Cancer Treatment and Research 2014; 2(4): 37-44 Published online August 30, 2014 (http://www.sciencepublishinggroup.com/j/jctr) doi: 10.11648/j.jctr.20140204.12 Comparative study of Gemcitabine
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationSeptember 10, Dear Dr. Clark,
September 10, 2015 Peter E. Clark, MD Chair, NCCN Bladder Cancer Guidelines (Version 2.2015) Associate Professor of Urologic Surgery Vanderbilt Ingram Cancer Center Nashville, TN 37232 Dear Dr. Clark,
More informationExpanding Role of the Medical Oncologist in the Management of Head and Neck Cancer Nicholas Choong and Everett Vokes DOI: /CA.2007.
Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer Nicholas Choong and Everett Vokes CA Cancer J Clin 2008;58;32-53; originally published online Dec 20, 2007; DOI: 10.3322/CA.2007.0004
More informationTherapy of Locally Advanced Head and Neck Cancer: State of the Art
Therapy of Locally Advanced Head and Neck Cancer: State of the Art Barbara Burtness, MD Chief, Head and Neck ncology Medical ncology Co-Leader Senior Member Fox Chase Cancer Center Philadelphia, PA Therapy
More informationHypopharynx. 1. Introduction. 1.1 General Information and Aetiology
Hypopharynx 1. Introduction 1.1 General Information and Aetiology The human pharynx is the part of the throat situated between the nasal cavity and the esophagus and can be divided into three parts: the
More informationCetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?
Cent. Eur. J. Med. 9(2) 2014 279-284 DOI: 10.2478/s11536-013-0154-9 Central European Journal of Medicine Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice? Jacopo Giuliani* 1, Marina
More information67 F, 40 PY Smoker, Past heavy alcohol consumer, h/o COPD, Congestive heart failure. Presentation: Lump left upper neck x 1 year, non-tender, no
67 F, 40 PY Smoker, Past heavy alcohol consumer, h/o COPD, Congestive heart failure. Presentation: Lump left upper neck x 1 year, non-tender, no overlying skin changes, gradually increasing in size. Recent
More informationSurf, Sea and Supracricoid Laryngectomy: A Queensland Experience. Jeeve Kanagalingam Associate Consultant Tan Tock Seng Hospital Singapore
Surf, Sea and Supracricoid Laryngectomy: A Queensland Experience Jeeve Kanagalingam Associate Consultant Tan Tock Seng Hospital Singapore Queensland 2500 times the size of Singapore Same population as
More informationNasopharyngeal Cancer:Role of Chemotherapy
Nasopharyngeal Cancer:Role of Chemotherapy PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 16/9/2017 2 nd Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More informationFINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma
Case Scenario 1 HNP: A 70 year old white male presents with dysphagia. The patient is a current smoker, current user of alcohol and is HPV positive. A CT of the Neck showed mass in the left pyriform sinus.
More informationHead and Neck Cancer Update Sandro V Porceddu
Head and Neck Cancer Update Sandro V Porceddu Director, Radiation Oncology Research Princess Alexandra Hospital, Brisbane Associate Professor, University of Queensland President, Trans Tasman Radiation
More informationLaryngeal Conservation February 2005
TITLE: Laryngeal Conservation SOURCE: Grand Rounds Presentation, UTMB, Dept. of Otolaryngology DATE: February 9, 2005 RESIDENT PHYSICIAN: Sarah Rodriguez, MD FACULTY ADVISOR: Shawn Newlands, MD, PhD, MBA
More informationPardeep Garg 1*, Parveen Kaur 2, Rajesh Vashistha 3, Rupinder Singh 4, Ishu Sharma 5. Original Research Article. Foundation, Ludhiana, Punjab, India.
Original Research Article Incidence and Severity of Oral Mucositis in Patients of Head and Neck Cancers Receiving Definitive Radiotherapy with or without Chemotherapy: A Hospital Based Study Pardeep Garg
More informationESMO Preceptorship Programme, Colorectal Cancer, Vienna
State of the art multimodal treatment of anal cancer ESMO Preceptorship Programme, Colorectal Cancer, Vienna Rob Glynne-Jones Mount Vernon Centre for Cancer Treatment Disclosures: last 5 years Speaker:
More informationAccepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience ( DOI: /hed.
DEFINING RISK LEVELS IN LOCALLY ADVANCED HEAD AND NECK CANCERS: A COMPARATIVE ANALYSIS OF CONCURRENT POSTOPERATIVE RADIATION PLUS CHEMOTHERAPY TRIALS OF THE EORTC (#22931) AND RTOG (#9501) Jacques Bernier,
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationQuality of life in patients treated for advanced hypopharyngeal or laryngeal cancer
European Annals of Otorhinolaryngology, Head and Neck diseases (2011) 128, 218 223 ORIGINAL ARTICLE Quality of life in patients treated for advanced hypopharyngeal or laryngeal cancer M. Guibert a, B.
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationRecent Advances & Ongoing Challenges in Head & Neck Cancers
Recent Advances & Ongoing Challenges in Head & Neck Cancers Robert Haddad, MD Disease Center Leader Head and Neck Oncology Program Dana Farber Cancer Institute Harvard Medical School Boston, MA Disclosures
More informationand neck cancers, 2018
Emerging systemic treatments for head and neck cancers, 2018 A. DIMITRIOS COLEVAS, MD PROFESSOR OF MEDICINE (ONCOLOGY) AND, BY COURTESY, OF OTOLARYNGOLOGY - HEAD AND NECK SURGERY AT THE STANFORD UNIVERSITY
More informationMolecular targeting agents in the context of primary chemoradiation strategies
CLINICAL REVIEW Molecular targeting agents in the context of primary chemoradiation strategies Simon Laban, MD, 1 * Chia Jung Wang, MD, 1 Adrian Münscher, MD, 1 Silke Tribius, MD, 2 Philippe Schafhausen,
More information